Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

BPC-157

Body Protection Compound-157, PL-14736, Pentadecapeptide BPC 157

Quick Stats
Studies 196
Trials 1
Score 3
2017 pubmed 51 citations

Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights.

Duzel. Antonija A; Vlainic. Josipa J; Antunovic. Marko M; Malekinusic. Dominik D; Vrdoljak. Borna B; Samara. Mariam M; Gojkovic. Slaven S; Krezic. Ivan I; Vidovic. Tinka T; Bilic. Zdenko Z; Knezevic. Mario M; Sever. Marko M; Lojo. Nermin N; Kokot. Antonio A; Kolovrat. Marijan M; Drmic. Domagoj D; Vukojevic. Jaksa J; Kralj. Tamara T; Kasnik. Katarina K; Siroglavic. Marko M; Seiwerth. Sven S; Sikiric. Predrag P

Key Findings

  • BPC‑157 (10 µg/kg) applied directly to the colon restored blood vessel connections and reduced pale, damaged areas.
  • Treated rats showed normal levels of oxidative stress marker MDA and balanced nitric‑oxide levels, indicating reduced tissue injury.
  • The peptide counteracted negative effects of nitric‑oxide blockers (L‑NAME) and boosted recovery after ischemia‑reperfusion injury.

Practical Outcomes

  • For biohackers, this study suggests BPC‑157 may have gut‑protective properties that could support healing after injury or inflammation. While the work was done in rats with a local bath application, it hints that oral or injectable BPC‑157 might aid gut health, but human data are still needed. If experimenting, start with low, scaled‑down doses and monitor gastrointestinal symptoms closely.

Summary

In rats with damaged colon tissue, a single local dose of the peptide BPC‑157 quickly repaired blood flow, lowered harmful oxidative stress, and kept the gut lining intact. The benefits seemed to work through the body’s nitric‑oxide system and even helped reverse damage caused by drugs that block nitric‑oxide.

Abstract

To provide new insights in treatment of colitis and ischemia and reperfusion in rats using stable gastric pentadecapeptide BPC 157. Medication [BPC 157, L-NAME, L-arginine (alone/combined), saline] was bath at the blood deprived colon segment. During reperfusion, medication was BPC 157 or saline. We recorded (USB microscope camera) vessel presentation through next 15 min of ischemic colitis (IC-rats) or reperfusion (removed ligations) (IC + RL-rats); oxidative stress as MDA (increased (IC- and IC + RL-rats)) and NO levels (decreased (IC-rats); increased (IC + RL-rats)) in colon tissue. IC + OB-rats [IC-rats had additional colon obstruction (OB)] for 3 d (IC + OB-rats), then received BPC 157 bath. Commonly, in colon segment (25 mm, 2 ligations on left colic artery and vein, 3 arcade vessels within ligated segment), in IC-, IC + RL-, IC + OB-rats, BPC 157 (10 μg/kg) bath (1 mL/rat) increased vessel presentation, inside/outside arcade interconnections quickly reappeared, mucosal folds were preserved and the pale areas were small and markedly reduced. BPC 157 counteracted worsening effects induced by L-NAME (5 mg) and L-arginine (100 mg). MDA- and NO-levels were normal in BPC 157 treated IC-rats and IC + RL-rats. In addition, on day 10, BPC 157-treated IC + OB-rats presented almost completely spared mucosa with very small pale areas and no gross mucosal defects; the treated colon segment was of normal diameter, and only small adhesions were present. BPC 157 is a fundamental treatment that quickly restores blood supply to the ischemically injured area and rapidly activates collaterals. This effect involves the NO system.

Study Information

Provider

pubmed

Year

2017

Date

2017-12-28T00:00:00.000Z

DOI

10.3748/wjg.v23.i48.8465

Citations

51

References

55